Clinical Study
Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors
Table 2
Log-rank tests for overall survival, distant metastases-free survival, and disease-free survival.
| | 5-year OS (%) | Log-Rank test value | 5-year DMFS (%) | Log-Rank test value | 5-year DFS (%) | Log-Rank test value |
| Age (years) | | 0.029 (between all) | | 0.403 (between all) | | 0.200 (between all) | ≤40 | 70.7 | 0.006 (≤40 : 41–64) | 81.8 | 0.259 (≤40 : 41–64) | 74.7 | 0.074 (≤40 : 41–64) | 41–64 | 92.2 | 0.326 (≤40 : ≥65) | 89.6 | 0.953 (≤40 : ≥65) | 86.0 | 0.523 (≤40 : ≥65) | ≥65 | 93.8 | 0.500 (41–64 : ≥65) | 76.2 | 0.294 (41–64 : ≥65) | 80.2 | 0.782 (41–64 : ≥65) |
| FIGO stage | | 0.481 (between all) | | 0.712 (between all) | | 0.335 (between all) | Ia | 100.0 | 0.385 (Ia : Ib) | 100.0 | 0.450 (Ia : Ib) | 100.0 | 0.240 (Ia : Ib) | Ib | 89.0 | 0.331 (Ia : IIa) | 86.1 | 0.424 (Ia : IIa) | 83.9 | 0.169 (Ia : IIa) | IIa | 83.6 | 0.433 (Ib : IIa) | 83.7 | 0.773 (Ib : IIa) | 75.7 | 0.441 (Ib : IIa) |
| Histology | | 0.494 | | 0.987 | | | Squamous | 88.8 | | 86.3 | | | | Others | 85.0 | | 84.8 | | | |
| Serum SCC antigen (ng/mL) | | 0.278 | | 0.218 | | 0.176 | ≤1.5 | 88.8 | | 89.8 | | 87.8 | | >1.5 | 84.4 | | 85.0 | | 79.0 | |
| Tumor size (cm) | | <0.001 | | <0.001 | | 0.058 | ≤4 | 94.7 | | 92.5 | | 86.7 | | >4 | 64.3 | | 59.6 | | 66.7 | |
| Depth of cervix invasion | | 0.162 | | 0.300 | | 0.255 | ≤1/2 | 100.0 | | 90.3 | | 87.6 | | >1/2 | 84.1 | | 85.1 | | 81.5 | |
| Parametrial invasion | | 0.093 | | 0.383 | | 0.300 | Negative | 90.7 | | 87.1 | | 84.6 | | Positive | 72.2 | | 79.4 | | 73.3 | |
| Resection margin involvement | | 0.432 | | 0.413 | | 0.612 | Negative | 88.3 | | 87.3 | | 83.4 | | Positive | 86.7 | | 79.4 | | 80.8 | |
| Lymphovascular invasion | | 0.417 | | 0.080 | | 0.124 | Negative | 92.4 | | 90.8 | | 86.6 | | Positive | 83.6 | | 81.1 | | 78.7 | |
| Lymph node involvement | | 0.061 (between all) | | 0.010 (between all) | | 0.033 (between all) | 0 | 92.8 | 0.265 (0 : 1-2) | 89.6 | 0.551 (0 : 1-2) | 87.8 | 0.604 (0 : 1-2) | 1-2 | 82.6 | 0.009 (0 : ≥3) | 87.0 | 0.001 (0 : ≥3) | 83.3 | 0.006 (0 : ≥3) | ≥3 | 60.0 | 0.407 (1-2 : ≥3) | 55.6 | 0.098 (1-2 : ≥3) | 50.0 | 0.174 (1-2 : ≥3) |
| Concurrent chemotherapy | | 0.895 | | 0.554 | | 0.871 | No | 92.8 | | 82.0 | | 82.5 | | Yes | 86.3 | | 88.4 | | 84.0 | |
|
|
OS: overall survival; DMFS: distant metastases-free survival; DFS: disease-free survival.
|